CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association
Recommendations
As issued by the authors
Evidence supports CYP2C19 genetic testing before oral P2Y12 inhibitors are prescribed in ACS or PCI
Precision approach (LOF carriers: ticagrelor or prasugrel; noncarriers: clopidogrel) reduces ischaemic events without increasing bleeding risk, per recent trials and meta-analyses
Original publication
CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association. Circulation. Published 20 June 2024. doi:10.
Summarised from the published abstract; every number is checked against it